世界のデュシェンヌ型筋ジストロフィー治療市場2020:企業別、地域別、種類・用途別

【英語タイトル】Global Duchenne Muscular Dystrophy Therapeutics Market 2020 by Company, Regions, Type and Application, Forecast to 2025

GlobalInfoResearchが出版した調査資料(GIR20MY04869)・商品コード:GIR20MY04869
・発行会社(調査会社):GlobalInfoResearch
・発行日:2020年5月
・ページ数:100
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,480 ⇒換算¥382,800見積依頼/購入/質問フォーム
Multi User(10名様閲覧用)USD5,220 ⇒換算¥574,200見積依頼/購入/質問フォーム
Corporate User(同一法人内共有可)USD6,960 ⇒換算¥765,600見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートでは、デュシェンヌ型筋ジストロフィー治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。デュシェンヌ型筋ジストロフィー治療の種類別市場規模(鎮痛剤、コルチコステロイド、プレドニゾロン、プレドニゾン、デフラザコート)、用途別市場規模(病院、クリニック、在宅医療)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・市場概要
・企業情報(販売量、市場シェア、製品概要、SWOT分析):Bristol-Myers Squibb、ReveraGen BioPharma (US)、Marathon、FibroGen (US)、Pfizer、Italfarmaco (Italy)、Sarepta Therapeutics (US)、PTC Therapeutics (US)、NS Pharma (US)、Santhera Pharmaceuticals (Switzerland)
・地域別グローバル市場分析 2015年-2020年
・デュシェンヌ型筋ジストロフィー治療の北米市場(アメリカ、カナダ、メキシコ)
・デュシェンヌ型筋ジストロフィー治療のヨーロッパ市場(ドイツ、イギリス、フランス、ロシア、イタリア)
・デュシェンヌ型筋ジストロフィー治療のアジア市場(中国、日本、韓国、インド、東南アジア、オーストラリア)
・デュシェンヌ型筋ジストロフィー治療の南米市場(ブラジル、アルゼンチン)
・デュシェンヌ型筋ジストロフィー治療の中東・アフリカ市場(サウジアラビア、トルコ、エジプト、南アフリカ)
・種類別分析:鎮痛剤、コルチコステロイド、プレドニゾロン、プレドニゾン、デフラザコート
・用途別分析:病院、クリニック、在宅医療
・地域別市場規模予測 2021年-2025年
・販売チャネル、流通業者、代理店
・調査の結果・結論
【レポートの概要】

Market Overview
The global Duchenne Muscular Dystrophy Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 27.7% in the forecast period of 2020 to 2025 and will expected to reach USD 2629.3 million by 2025, from USD 989.7 million in 2019.

The Duchenne Muscular Dystrophy Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Duchenne Muscular Dystrophy Therapeutics market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Duchenne Muscular Dystrophy Therapeutics market has been segmented into:
Pain Management Drugs
Corticosteroids
Prednisolone
Prednisone
Deflazacort

By Application, Duchenne Muscular Dystrophy Therapeutics has been segmented into:
Hospitals
Clinics
Home Care Settings

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Duchenne Muscular Dystrophy Therapeutics market presented in the report. This section sheds light on the sales growth of different regional and country-level Duchenne Muscular Dystrophy Therapeutics markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Duchenne Muscular Dystrophy Therapeutics market.

The report offers in-depth assessment of the growth and other aspects of the Duchenne Muscular Dystrophy Therapeutics market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Duchenne Muscular Dystrophy Therapeutics Market Share Analysis
Duchenne Muscular Dystrophy Therapeutics competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Duchenne Muscular Dystrophy Therapeutics sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Duchenne Muscular Dystrophy Therapeutics sales, revenue and market share for each player covered in this report.

The major players covered in Duchenne Muscular Dystrophy Therapeutics are:
Bristol-Myers Squibb
ReveraGen BioPharma (US)
Marathon
FibroGen (US)
Pfizer
Italfarmaco (Italy)
Sarepta Therapeutics (US)
PTC Therapeutics (US)
NS Pharma (US)
Santhera Pharmaceuticals (Switzerland)

【レポートの目次】

Table of Contents

1 Duchenne Muscular Dystrophy Therapeutics Market Overview
1.1 Product Overview and Scope of Duchenne Muscular Dystrophy Therapeutics
1.2 Classification of Duchenne Muscular Dystrophy Therapeutics by Type
1.2.1 Global Duchenne Muscular Dystrophy Therapeutics Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Type in 2019
1.2.3 Pain Management Drugs
1.2.4 Corticosteroids
1.2.5 Prednisolone
1.2.6 Prednisone
1.2.7 Deflazacort
1.3 Global Duchenne Muscular Dystrophy Therapeutics Market by Application
1.3.1 Overview: Global Duchenne Muscular Dystrophy Therapeutics Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Home Care Settings
1.4 Global Duchenne Muscular Dystrophy Therapeutics Market by Regions
1.4.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Duchenne Muscular Dystrophy Therapeutics (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Duchenne Muscular Dystrophy Therapeutics Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Duchenne Muscular Dystrophy Therapeutics Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Duchenne Muscular Dystrophy Therapeutics Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Duchenne Muscular Dystrophy Therapeutics Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Duchenne Muscular Dystrophy Therapeutics Status and Prospect (2015-2025)
2 Company Profiles
2.1 Bristol-Myers Squibb
2.1.1 Bristol-Myers Squibb Details
2.1.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Bristol-Myers Squibb SWOT Analysis
2.1.4 Bristol-Myers Squibb Product and Services
2.1.5 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.2 ReveraGen BioPharma (US)
2.2.1 ReveraGen BioPharma (US) Details
2.2.2 ReveraGen BioPharma (US) Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 ReveraGen BioPharma (US) SWOT Analysis
2.2.4 ReveraGen BioPharma (US) Product and Services
2.2.5 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.3 Marathon
2.3.1 Marathon Details
2.3.2 Marathon Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Marathon SWOT Analysis
2.3.4 Marathon Product and Services
2.3.5 Marathon Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.4 FibroGen (US)
2.4.1 FibroGen (US) Details
2.4.2 FibroGen (US) Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 FibroGen (US) SWOT Analysis
2.4.4 FibroGen (US) Product and Services
2.4.5 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Pfizer SWOT Analysis
2.5.4 Pfizer Product and Services
2.5.5 Pfizer Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.6 Italfarmaco (Italy)
2.6.1 Italfarmaco (Italy) Details
2.6.2 Italfarmaco (Italy) Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Italfarmaco (Italy) SWOT Analysis
2.6.4 Italfarmaco (Italy) Product and Services
2.6.5 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.7 Sarepta Therapeutics (US)
2.7.1 Sarepta Therapeutics (US) Details
2.7.2 Sarepta Therapeutics (US) Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Sarepta Therapeutics (US) SWOT Analysis
2.7.4 Sarepta Therapeutics (US) Product and Services
2.7.5 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.8 PTC Therapeutics (US)
2.8.1 PTC Therapeutics (US) Details
2.8.2 PTC Therapeutics (US) Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 PTC Therapeutics (US) SWOT Analysis
2.8.4 PTC Therapeutics (US) Product and Services
2.8.5 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.9 NS Pharma (US)
2.9.1 NS Pharma (US) Details
2.9.2 NS Pharma (US) Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 NS Pharma (US) SWOT Analysis
2.9.4 NS Pharma (US) Product and Services
2.9.5 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.10 Santhera Pharmaceuticals (Switzerland)
2.10.1 Santhera Pharmaceuticals (Switzerland) Details
2.10.2 Santhera Pharmaceuticals (Switzerland) Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Santhera Pharmaceuticals (Switzerland) SWOT Analysis
2.10.4 Santhera Pharmaceuticals (Switzerland) Product and Services
2.10.5 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Duchenne Muscular Dystrophy Therapeutics Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Duchenne Muscular Dystrophy Therapeutics Players Market Share
3.2.2 Top 10 Duchenne Muscular Dystrophy Therapeutics Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Duchenne Muscular Dystrophy Therapeutics Revenue and Market Share by Regions
4.2 North America Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
4.3 Europe Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
4.5 South America Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
5 North America Duchenne Muscular Dystrophy Therapeutics Revenue by Countries
5.1 North America Duchenne Muscular Dystrophy Therapeutics Revenue by Countries (2015-2020)
5.2 USA Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
5.3 Canada Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
5.4 Mexico Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
6 Europe Duchenne Muscular Dystrophy Therapeutics Revenue by Countries
6.1 Europe Duchenne Muscular Dystrophy Therapeutics Revenue by Countries (2015-2020)
6.2 Germany Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
6.3 UK Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
6.4 France Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
6.5 Russia Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
6.6 Italy Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue by Countries
7.1 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue by Countries (2015-2020)
7.2 China Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
7.3 Japan Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
7.4 Korea Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
7.5 India Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
8 South America Duchenne Muscular Dystrophy Therapeutics Revenue by Countries
8.1 South America Duchenne Muscular Dystrophy Therapeutics Revenue by Countries (2015-2020)
8.2 Brazil Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
8.3 Argentina Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Duchenne Muscular Dystrophy Therapeutics by Countries
9.1 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Revenue by Countries (2015-2020)
9.2 Saudi Arabia Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
9.3 UAE Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
9.4 Egypt Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
9.5 South Africa Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Duchenne Muscular Dystrophy Therapeutics Revenue and Market Share by Type (2015-2020)
10.2 Global Duchenne Muscular Dystrophy Therapeutics Market Forecast by Type (2019-2024)
10.3 Pain Management Drugs Revenue Growth Rate (2015-2025)
10.4 Corticosteroids Revenue Growth Rate (2015-2025)
10.5 Prednisolone Revenue Growth Rate (2015-2025)
10.6 Prednisone Revenue Growth Rate (2015-2025)
10.7 Deflazacort Revenue Growth Rate (2015-2025)
11 Global Duchenne Muscular Dystrophy Therapeutics Market Segment by Application
11.1 Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Application (2015-2020)
11.2 Duchenne Muscular Dystrophy Therapeutics Market Forecast by Application (2019-2024)
11.3 Hospitals Revenue Growth (2015-2020)
11.4 Clinics Revenue Growth (2015-2020)
11.5 Home Care Settings Revenue Growth (2015-2020)
12 Global Duchenne Muscular Dystrophy Therapeutics Market Size Forecast (2021-2025)
12.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size Forecast (2021-2025)
12.2 Global Duchenne Muscular Dystrophy Therapeutics Market Forecast by Regions (2021-2025)
12.3 North America Duchenne Muscular Dystrophy Therapeutics Revenue Market Forecast (2021-2025)
12.4 Europe Duchenne Muscular Dystrophy Therapeutics Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue Market Forecast (2021-2025)
12.6 South America Duchenne Muscular Dystrophy Therapeutics Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Duchenne Muscular Dystrophy Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Bristol-Myers Squibb Corporate Information, Location and Competitors
Table 6. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Major Business
Table 7. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Total Revenue (USD Million) (2017-2018)
Table 8. Bristol-Myers Squibb SWOT Analysis
Table 9. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Product and Solutions
Table 10. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. ReveraGen BioPharma (US) Corporate Information, Location and Competitors
Table 12. ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Major Business
Table 13. ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Total Revenue (USD Million) (2018-2019)
Table 14. ReveraGen BioPharma (US) SWOT Analysis
Table 15. ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Product and Solutions
Table 16. ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Marathon Corporate Information, Location and Competitors
Table 18. Marathon Duchenne Muscular Dystrophy Therapeutics Major Business
Table 19. Marathon Duchenne Muscular Dystrophy Therapeutics Total Revenue (USD Million) (2017-2018)
Table 20. Marathon SWOT Analysis
Table 21. Marathon Duchenne Muscular Dystrophy Therapeutics Product and Solutions
Table 22. Marathon Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. FibroGen (US) Corporate Information, Location and Competitors
Table 24. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Major Business
Table 25. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Total Revenue (USD Million) (2017-2018)
Table 26. FibroGen (US) SWOT Analysis
Table 27. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Product and Solutions
Table 28. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Pfizer Corporate Information, Location and Competitors
Table 30. Pfizer Duchenne Muscular Dystrophy Therapeutics Major Business
Table 31. Pfizer Duchenne Muscular Dystrophy Therapeutics Total Revenue (USD Million) (2017-2018)
Table 32. Pfizer SWOT Analysis
Table 33. Pfizer Duchenne Muscular Dystrophy Therapeutics Product and Solutions
Table 34. Pfizer Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Italfarmaco (Italy) Corporate Information, Location and Competitors
Table 36. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Major Business
Table 37. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Total Revenue (USD Million) (2017-2018)
Table 38. Italfarmaco (Italy) SWOT Analysis
Table 39. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Product and Solutions
Table 40. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Sarepta Therapeutics (US) Corporate Information, Location and Competitors
Table 42. Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Major Business
Table 43. Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Total Revenue (USD Million) (2017-2018)
Table 44. Sarepta Therapeutics (US) SWOT Analysis
Table 45. Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product and Solutions
Table 46. Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. PTC Therapeutics (US) Corporate Information, Location and Competitors
Table 48. PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Major Business
Table 49. PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Total Revenue (USD Million) (2017-2018)
Table 50. PTC Therapeutics (US) SWOT Analysis
Table 51. PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product and Solutions
Table 52. PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. NS Pharma (US) Corporate Information, Location and Competitors
Table 54. NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Major Business
Table 55. NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Total Revenue (USD Million) (2017-2018)
Table 56. NS Pharma (US) SWOT Analysis
Table 57. NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Product and Solutions
Table 58. NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Santhera Pharmaceuticals (Switzerland) Corporate Information, Location and Competitors
Table 60. Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Major Business
Table 61. Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Total Revenue (USD Million) (2017-2018)
Table 62. Santhera Pharmaceuticals (Switzerland) SWOT Analysis
Table 63. Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Product and Solutions
Table 64. Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Global Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) by Players (2015-2020)
Table 66. Global Duchenne Muscular Dystrophy Therapeutics Revenue Share by Players (2015-2020)
Table 67. Global Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) by Regions (2015-2020)
Table 68. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Regions (2015-2020)
Table 69. North America Duchenne Muscular Dystrophy Therapeutics Revenue by Countries (2015-2020)
Table 70. North America Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Countries (2015-2020)
Table 71. Europe Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 72. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 73. South America Duchenne Muscular Dystrophy Therapeutics Revenue by Countries (2015-2020)
Table 74. South America Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Countries (2015-2020)
Table 75. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 76. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Countries (2015-2020)
Table 77. Global Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) by Type (2015-2020)
Table 78. Global Duchenne Muscular Dystrophy Therapeutics Revenue Share by Type (2015-2020)
Table 79. Global Duchenne Muscular Dystrophy Therapeutics Revenue Forecast by Type (2021-2025)
Table 80. Global Duchenne Muscular Dystrophy Therapeutics Revenue by Application (2015-2020)
Table 81. Global Duchenne Muscular Dystrophy Therapeutics Revenue Share by Application (2015-2020)
Table 82. Global Duchenne Muscular Dystrophy Therapeutics Revenue Forecast by Application (2021-2025)
Table 83. Global Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Duchenne Muscular Dystrophy Therapeutics Picture
Figure 2. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Type in 2019
Figure 3. Pain Management Drugs Picture
Figure 4. Corticosteroids Picture
Figure 5. Prednisolone Picture
Figure 6. Prednisone Picture
Figure 7. Deflazacort Picture
Figure 8. Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Application in 2019
Figure 9. Hospitals Picture
Figure 10. Clinics Picture
Figure 11. Home Care Settings Picture
Figure 12. Global Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million) and Growth Rate (2015-2025)
Figure 13. North America Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Europe Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. South America Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Global Duchenne Muscular Dystrophy Therapeutics Revenue Share by Players in 2019
Figure 20. Global Top 5 Players Duchenne Muscular Dystrophy Therapeutics Revenue Market Share in 2019
Figure 21. Global Top 10 Players Duchenne Muscular Dystrophy Therapeutics Revenue Market Share in 2019
Figure 22. Key Players Market Share Trend
Figure 23. Global Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 24. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Regions (2015-2020)
Figure 25. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Regions in 2018
Figure 26. North America Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 27. Europe Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 28. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 29. South America Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 30. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 31. North America Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 32. North America Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Countries in 2019
Figure 33. USA Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 34. Canada Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 35. Mexico Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 36. Europe Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 37. Europe Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Countries in 2019
Figure 38. Germany Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 39. UK Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 40. France Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 41. Russia Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 42. Italy Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 43. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 44. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Countries in 2019
Figure 45. China Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 46. Japan Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 47. Korea Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 48. India Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 49. Southeast Asia Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 50. South America Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 51. South America Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Countries in 2019
Figure 52. Brazil Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 53. Argentina Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 54. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 55. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Countries in 2019
Figure 56. Saudi Arabia Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 57. UAE Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 58. Egypt Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 59. South Africa Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 60. Global Duchenne Muscular Dystrophy Therapeutics Revenue Share by Type (2015-2020)
Figure 61. Global Duchenne Muscular Dystrophy Therapeutics Revenue Share by Type in 2019
Figure 62. Global Duchenne Muscular Dystrophy Therapeutics Market Share Forecast by Type (2021-2025)
Figure 63. Global Pain Management Drugs Revenue Growth Rate (2015-2020)
Figure 64. Global Corticosteroids Revenue Growth Rate (2015-2020)
Figure 65. Global Prednisolone Revenue Growth Rate (2015-2020)
Figure 66. Global Prednisone Revenue Growth Rate (2015-2020)
Figure 67. Global Deflazacort Revenue Growth Rate (2015-2020)
Figure 68. Global Duchenne Muscular Dystrophy Therapeutics Revenue Share by Application (2015-2020)
Figure 69. Global Duchenne Muscular Dystrophy Therapeutics Revenue Share by Application in 2019
Figure 70. Global Duchenne Muscular Dystrophy Therapeutics Market Share Forecast by Application (2021-2025)
Figure 71. Global Hospitals Revenue Growth Rate (2015-2020)
Figure 72. Global Clinics Revenue Growth Rate (2015-2020)
Figure 73. Global Home Care Settings Revenue Growth Rate (2015-2020)
Figure 74. Global Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 75. Global Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 76. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share Forecast by Regions (2021-2025)
Figure 77. North America Duchenne Muscular Dystrophy Therapeutics Revenue Market Forecast (2021-2025)
Figure 78. Europe Duchenne Muscular Dystrophy Therapeutics Revenue Market Forecast (2021-2025)
Figure 79. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue Market Forecast (2021-2025)
Figure 80. South America Duchenne Muscular Dystrophy Therapeutics Revenue Market Forecast (2021-2025)
Figure 81. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Revenue Market Forecast (2021-2025)
Figure 82. Sales Channel: Direct Channel vs Indirect Channel


【掲載企業】

Bristol-Myers Squibb、ReveraGen BioPharma (US)、Marathon、FibroGen (US)、Pfizer、Italfarmaco (Italy)、Sarepta Therapeutics (US)、PTC Therapeutics (US)、NS Pharma (US)、Santhera Pharmaceuticals (Switzerland)

★調査レポート[世界のデュシェンヌ型筋ジストロフィー治療市場2020:企業別、地域別、種類・用途別] (コード:GIR20MY04869)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のデュシェンヌ型筋ジストロフィー治療市場2020:企業別、地域別、種類・用途別]についてメールでお問い合わせ

世界のデュシェンヌ型筋ジストロフィー治療市場2020:企業別、地域別、種類・用途別

【英語タイトル】Global Duchenne Muscular Dystrophy Therapeutics Market 2020 by Company, Regions, Type and Application, Forecast to 2025

GlobalInfoResearchが出版した調査資料(GIR20MY04869)・商品コード:GIR20MY04869
・発行会社(調査会社):GlobalInfoResearch
・発行日:2020年5月
・ページ数:100
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,480 ⇒換算¥382,800見積依頼/購入/質問フォーム
Multi User(10名様閲覧用)USD5,220 ⇒換算¥574,200見積依頼/購入/質問フォーム
Corporate User(同一法人内共有可)USD6,960 ⇒換算¥765,600見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートでは、デュシェンヌ型筋ジストロフィー治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。デュシェンヌ型筋ジストロフィー治療の種類別市場規模(鎮痛剤、コルチコステロイド、プレドニゾロン、プレドニゾン、デフラザコート)、用途別市場規模(病院、クリニック、在宅医療)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・市場概要
・企業情報(販売量、市場シェア、製品概要、SWOT分析):Bristol-Myers Squibb、ReveraGen BioPharma (US)、Marathon、FibroGen (US)、Pfizer、Italfarmaco (Italy)、Sarepta Therapeutics (US)、PTC Therapeutics (US)、NS Pharma (US)、Santhera Pharmaceuticals (Switzerland)
・地域別グローバル市場分析 2015年-2020年
・デュシェンヌ型筋ジストロフィー治療の北米市場(アメリカ、カナダ、メキシコ)
・デュシェンヌ型筋ジストロフィー治療のヨーロッパ市場(ドイツ、イギリス、フランス、ロシア、イタリア)
・デュシェンヌ型筋ジストロフィー治療のアジア市場(中国、日本、韓国、インド、東南アジア、オーストラリア)
・デュシェンヌ型筋ジストロフィー治療の南米市場(ブラジル、アルゼンチン)
・デュシェンヌ型筋ジストロフィー治療の中東・アフリカ市場(サウジアラビア、トルコ、エジプト、南アフリカ)
・種類別分析:鎮痛剤、コルチコステロイド、プレドニゾロン、プレドニゾン、デフラザコート
・用途別分析:病院、クリニック、在宅医療
・地域別市場規模予測 2021年-2025年
・販売チャネル、流通業者、代理店
・調査の結果・結論
【レポートの概要】

Market Overview
The global Duchenne Muscular Dystrophy Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 27.7% in the forecast period of 2020 to 2025 and will expected to reach USD 2629.3 million by 2025, from USD 989.7 million in 2019.

The Duchenne Muscular Dystrophy Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Duchenne Muscular Dystrophy Therapeutics market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Duchenne Muscular Dystrophy Therapeutics market has been segmented into:
Pain Management Drugs
Corticosteroids
Prednisolone
Prednisone
Deflazacort

By Application, Duchenne Muscular Dystrophy Therapeutics has been segmented into:
Hospitals
Clinics
Home Care Settings

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Duchenne Muscular Dystrophy Therapeutics market presented in the report. This section sheds light on the sales growth of different regional and country-level Duchenne Muscular Dystrophy Therapeutics markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Duchenne Muscular Dystrophy Therapeutics market.

The report offers in-depth assessment of the growth and other aspects of the Duchenne Muscular Dystrophy Therapeutics market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Duchenne Muscular Dystrophy Therapeutics Market Share Analysis
Duchenne Muscular Dystrophy Therapeutics competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Duchenne Muscular Dystrophy Therapeutics sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Duchenne Muscular Dystrophy Therapeutics sales, revenue and market share for each player covered in this report.

The major players covered in Duchenne Muscular Dystrophy Therapeutics are:
Bristol-Myers Squibb
ReveraGen BioPharma (US)
Marathon
FibroGen (US)
Pfizer
Italfarmaco (Italy)
Sarepta Therapeutics (US)
PTC Therapeutics (US)
NS Pharma (US)
Santhera Pharmaceuticals (Switzerland)

【レポートの目次】

Table of Contents

1 Duchenne Muscular Dystrophy Therapeutics Market Overview
1.1 Product Overview and Scope of Duchenne Muscular Dystrophy Therapeutics
1.2 Classification of Duchenne Muscular Dystrophy Therapeutics by Type
1.2.1 Global Duchenne Muscular Dystrophy Therapeutics Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Type in 2019
1.2.3 Pain Management Drugs
1.2.4 Corticosteroids
1.2.5 Prednisolone
1.2.6 Prednisone
1.2.7 Deflazacort
1.3 Global Duchenne Muscular Dystrophy Therapeutics Market by Application
1.3.1 Overview: Global Duchenne Muscular Dystrophy Therapeutics Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Home Care Settings
1.4 Global Duchenne Muscular Dystrophy Therapeutics Market by Regions
1.4.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Duchenne Muscular Dystrophy Therapeutics (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Duchenne Muscular Dystrophy Therapeutics Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Duchenne Muscular Dystrophy Therapeutics Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Duchenne Muscular Dystrophy Therapeutics Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Duchenne Muscular Dystrophy Therapeutics Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Duchenne Muscular Dystrophy Therapeutics Status and Prospect (2015-2025)
2 Company Profiles
2.1 Bristol-Myers Squibb
2.1.1 Bristol-Myers Squibb Details
2.1.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Bristol-Myers Squibb SWOT Analysis
2.1.4 Bristol-Myers Squibb Product and Services
2.1.5 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.2 ReveraGen BioPharma (US)
2.2.1 ReveraGen BioPharma (US) Details
2.2.2 ReveraGen BioPharma (US) Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 ReveraGen BioPharma (US) SWOT Analysis
2.2.4 ReveraGen BioPharma (US) Product and Services
2.2.5 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.3 Marathon
2.3.1 Marathon Details
2.3.2 Marathon Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Marathon SWOT Analysis
2.3.4 Marathon Product and Services
2.3.5 Marathon Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.4 FibroGen (US)
2.4.1 FibroGen (US) Details
2.4.2 FibroGen (US) Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 FibroGen (US) SWOT Analysis
2.4.4 FibroGen (US) Product and Services
2.4.5 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Pfizer SWOT Analysis
2.5.4 Pfizer Product and Services
2.5.5 Pfizer Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.6 Italfarmaco (Italy)
2.6.1 Italfarmaco (Italy) Details
2.6.2 Italfarmaco (Italy) Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Italfarmaco (Italy) SWOT Analysis
2.6.4 Italfarmaco (Italy) Product and Services
2.6.5 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.7 Sarepta Therapeutics (US)
2.7.1 Sarepta Therapeutics (US) Details
2.7.2 Sarepta Therapeutics (US) Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Sarepta Therapeutics (US) SWOT Analysis
2.7.4 Sarepta Therapeutics (US) Product and Services
2.7.5 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.8 PTC Therapeutics (US)
2.8.1 PTC Therapeutics (US) Details
2.8.2 PTC Therapeutics (US) Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 PTC Therapeutics (US) SWOT Analysis
2.8.4 PTC Therapeutics (US) Product and Services
2.8.5 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.9 NS Pharma (US)
2.9.1 NS Pharma (US) Details
2.9.2 NS Pharma (US) Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 NS Pharma (US) SWOT Analysis
2.9.4 NS Pharma (US) Product and Services
2.9.5 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.10 Santhera Pharmaceuticals (Switzerland)
2.10.1 Santhera Pharmaceuticals (Switzerland) Details
2.10.2 Santhera Pharmaceuticals (Switzerland) Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Santhera Pharmaceuticals (Switzerland) SWOT Analysis
2.10.4 Santhera Pharmaceuticals (Switzerland) Product and Services
2.10.5 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Duchenne Muscular Dystrophy Therapeutics Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Duchenne Muscular Dystrophy Therapeutics Players Market Share
3.2.2 Top 10 Duchenne Muscular Dystrophy Therapeutics Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Duchenne Muscular Dystrophy Therapeutics Revenue and Market Share by Regions
4.2 North America Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
4.3 Europe Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
4.5 South America Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
5 North America Duchenne Muscular Dystrophy Therapeutics Revenue by Countries
5.1 North America Duchenne Muscular Dystrophy Therapeutics Revenue by Countries (2015-2020)
5.2 USA Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
5.3 Canada Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
5.4 Mexico Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
6 Europe Duchenne Muscular Dystrophy Therapeutics Revenue by Countries
6.1 Europe Duchenne Muscular Dystrophy Therapeutics Revenue by Countries (2015-2020)
6.2 Germany Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
6.3 UK Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
6.4 France Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
6.5 Russia Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
6.6 Italy Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue by Countries
7.1 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue by Countries (2015-2020)
7.2 China Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
7.3 Japan Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
7.4 Korea Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
7.5 India Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
8 South America Duchenne Muscular Dystrophy Therapeutics Revenue by Countries
8.1 South America Duchenne Muscular Dystrophy Therapeutics Revenue by Countries (2015-2020)
8.2 Brazil Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
8.3 Argentina Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Duchenne Muscular Dystrophy Therapeutics by Countries
9.1 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Revenue by Countries (2015-2020)
9.2 Saudi Arabia Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
9.3 UAE Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
9.4 Egypt Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
9.5 South Africa Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Duchenne Muscular Dystrophy Therapeutics Revenue and Market Share by Type (2015-2020)
10.2 Global Duchenne Muscular Dystrophy Therapeutics Market Forecast by Type (2019-2024)
10.3 Pain Management Drugs Revenue Growth Rate (2015-2025)
10.4 Corticosteroids Revenue Growth Rate (2015-2025)
10.5 Prednisolone Revenue Growth Rate (2015-2025)
10.6 Prednisone Revenue Growth Rate (2015-2025)
10.7 Deflazacort Revenue Growth Rate (2015-2025)
11 Global Duchenne Muscular Dystrophy Therapeutics Market Segment by Application
11.1 Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Application (2015-2020)
11.2 Duchenne Muscular Dystrophy Therapeutics Market Forecast by Application (2019-2024)
11.3 Hospitals Revenue Growth (2015-2020)
11.4 Clinics Revenue Growth (2015-2020)
11.5 Home Care Settings Revenue Growth (2015-2020)
12 Global Duchenne Muscular Dystrophy Therapeutics Market Size Forecast (2021-2025)
12.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size Forecast (2021-2025)
12.2 Global Duchenne Muscular Dystrophy Therapeutics Market Forecast by Regions (2021-2025)
12.3 North America Duchenne Muscular Dystrophy Therapeutics Revenue Market Forecast (2021-2025)
12.4 Europe Duchenne Muscular Dystrophy Therapeutics Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue Market Forecast (2021-2025)
12.6 South America Duchenne Muscular Dystrophy Therapeutics Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Duchenne Muscular Dystrophy Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Bristol-Myers Squibb Corporate Information, Location and Competitors
Table 6. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Major Business
Table 7. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Total Revenue (USD Million) (2017-2018)
Table 8. Bristol-Myers Squibb SWOT Analysis
Table 9. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Product and Solutions
Table 10. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. ReveraGen BioPharma (US) Corporate Information, Location and Competitors
Table 12. ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Major Business
Table 13. ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Total Revenue (USD Million) (2018-2019)
Table 14. ReveraGen BioPharma (US) SWOT Analysis
Table 15. ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Product and Solutions
Table 16. ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Marathon Corporate Information, Location and Competitors
Table 18. Marathon Duchenne Muscular Dystrophy Therapeutics Major Business
Table 19. Marathon Duchenne Muscular Dystrophy Therapeutics Total Revenue (USD Million) (2017-2018)
Table 20. Marathon SWOT Analysis
Table 21. Marathon Duchenne Muscular Dystrophy Therapeutics Product and Solutions
Table 22. Marathon Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. FibroGen (US) Corporate Information, Location and Competitors
Table 24. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Major Business
Table 25. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Total Revenue (USD Million) (2017-2018)
Table 26. FibroGen (US) SWOT Analysis
Table 27. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Product and Solutions
Table 28. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Pfizer Corporate Information, Location and Competitors
Table 30. Pfizer Duchenne Muscular Dystrophy Therapeutics Major Business
Table 31. Pfizer Duchenne Muscular Dystrophy Therapeutics Total Revenue (USD Million) (2017-2018)
Table 32. Pfizer SWOT Analysis
Table 33. Pfizer Duchenne Muscular Dystrophy Therapeutics Product and Solutions
Table 34. Pfizer Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Italfarmaco (Italy) Corporate Information, Location and Competitors
Table 36. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Major Business
Table 37. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Total Revenue (USD Million) (2017-2018)
Table 38. Italfarmaco (Italy) SWOT Analysis
Table 39. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Product and Solutions
Table 40. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Sarepta Therapeutics (US) Corporate Information, Location and Competitors
Table 42. Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Major Business
Table 43. Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Total Revenue (USD Million) (2017-2018)
Table 44. Sarepta Therapeutics (US) SWOT Analysis
Table 45. Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product and Solutions
Table 46. Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. PTC Therapeutics (US) Corporate Information, Location and Competitors
Table 48. PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Major Business
Table 49. PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Total Revenue (USD Million) (2017-2018)
Table 50. PTC Therapeutics (US) SWOT Analysis
Table 51. PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product and Solutions
Table 52. PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. NS Pharma (US) Corporate Information, Location and Competitors
Table 54. NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Major Business
Table 55. NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Total Revenue (USD Million) (2017-2018)
Table 56. NS Pharma (US) SWOT Analysis
Table 57. NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Product and Solutions
Table 58. NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Santhera Pharmaceuticals (Switzerland) Corporate Information, Location and Competitors
Table 60. Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Major Business
Table 61. Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Total Revenue (USD Million) (2017-2018)
Table 62. Santhera Pharmaceuticals (Switzerland) SWOT Analysis
Table 63. Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Product and Solutions
Table 64. Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Global Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) by Players (2015-2020)
Table 66. Global Duchenne Muscular Dystrophy Therapeutics Revenue Share by Players (2015-2020)
Table 67. Global Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) by Regions (2015-2020)
Table 68. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Regions (2015-2020)
Table 69. North America Duchenne Muscular Dystrophy Therapeutics Revenue by Countries (2015-2020)
Table 70. North America Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Countries (2015-2020)
Table 71. Europe Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 72. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 73. South America Duchenne Muscular Dystrophy Therapeutics Revenue by Countries (2015-2020)
Table 74. South America Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Countries (2015-2020)
Table 75. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 76. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Countries (2015-2020)
Table 77. Global Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) by Type (2015-2020)
Table 78. Global Duchenne Muscular Dystrophy Therapeutics Revenue Share by Type (2015-2020)
Table 79. Global Duchenne Muscular Dystrophy Therapeutics Revenue Forecast by Type (2021-2025)
Table 80. Global Duchenne Muscular Dystrophy Therapeutics Revenue by Application (2015-2020)
Table 81. Global Duchenne Muscular Dystrophy Therapeutics Revenue Share by Application (2015-2020)
Table 82. Global Duchenne Muscular Dystrophy Therapeutics Revenue Forecast by Application (2021-2025)
Table 83. Global Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Duchenne Muscular Dystrophy Therapeutics Picture
Figure 2. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Type in 2019
Figure 3. Pain Management Drugs Picture
Figure 4. Corticosteroids Picture
Figure 5. Prednisolone Picture
Figure 6. Prednisone Picture
Figure 7. Deflazacort Picture
Figure 8. Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Application in 2019
Figure 9. Hospitals Picture
Figure 10. Clinics Picture
Figure 11. Home Care Settings Picture
Figure 12. Global Duchenne Muscular Dystrophy Therapeutics Revenue (USD Million) and Growth Rate (2015-2025)
Figure 13. North America Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Europe Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. South America Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Global Duchenne Muscular Dystrophy Therapeutics Revenue Share by Players in 2019
Figure 20. Global Top 5 Players Duchenne Muscular Dystrophy Therapeutics Revenue Market Share in 2019
Figure 21. Global Top 10 Players Duchenne Muscular Dystrophy Therapeutics Revenue Market Share in 2019
Figure 22. Key Players Market Share Trend
Figure 23. Global Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 24. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Regions (2015-2020)
Figure 25. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Regions in 2018
Figure 26. North America Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 27. Europe Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 28. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 29. South America Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 30. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 31. North America Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 32. North America Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Countries in 2019
Figure 33. USA Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 34. Canada Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 35. Mexico Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 36. Europe Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 37. Europe Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Countries in 2019
Figure 38. Germany Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 39. UK Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 40. France Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 41. Russia Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 42. Italy Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 43. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 44. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Countries in 2019
Figure 45. China Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 46. Japan Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 47. Korea Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 48. India Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 49. Southeast Asia Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 50. South America Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 51. South America Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Countries in 2019
Figure 52. Brazil Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 53. Argentina Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 54. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 55. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Countries in 2019
Figure 56. Saudi Arabia Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 57. UAE Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 58. Egypt Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 59. South Africa Duchenne Muscular Dystrophy Therapeutics Revenue and Growth Rate (2015-2020)
Figure 60. Global Duchenne Muscular Dystrophy Therapeutics Revenue Share by Type (2015-2020)
Figure 61. Global Duchenne Muscular Dystrophy Therapeutics Revenue Share by Type in 2019
Figure 62. Global Duchenne Muscular Dystrophy Therapeutics Market Share Forecast by Type (2021-2025)
Figure 63. Global Pain Management Drugs Revenue Growth Rate (2015-2020)
Figure 64. Global Corticosteroids Revenue Growth Rate (2015-2020)
Figure 65. Global Prednisolone Revenue Growth Rate (2015-2020)
Figure 66. Global Prednisone Revenue Growth Rate (2015-2020)
Figure 67. Global Deflazacort Revenue Growth Rate (2015-2020)
Figure 68. Global Duchenne Muscular Dystrophy Therapeutics Revenue Share by Application (2015-2020)
Figure 69. Global Duchenne Muscular Dystrophy Therapeutics Revenue Share by Application in 2019
Figure 70. Global Duchenne Muscular Dystrophy Therapeutics Market Share Forecast by Application (2021-2025)
Figure 71. Global Hospitals Revenue Growth Rate (2015-2020)
Figure 72. Global Clinics Revenue Growth Rate (2015-2020)
Figure 73. Global Home Care Settings Revenue Growth Rate (2015-2020)
Figure 74. Global Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 75. Global Duchenne Muscular Dystrophy Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 76. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share Forecast by Regions (2021-2025)
Figure 77. North America Duchenne Muscular Dystrophy Therapeutics Revenue Market Forecast (2021-2025)
Figure 78. Europe Duchenne Muscular Dystrophy Therapeutics Revenue Market Forecast (2021-2025)
Figure 79. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue Market Forecast (2021-2025)
Figure 80. South America Duchenne Muscular Dystrophy Therapeutics Revenue Market Forecast (2021-2025)
Figure 81. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Revenue Market Forecast (2021-2025)
Figure 82. Sales Channel: Direct Channel vs Indirect Channel


【掲載企業】

Bristol-Myers Squibb、ReveraGen BioPharma (US)、Marathon、FibroGen (US)、Pfizer、Italfarmaco (Italy)、Sarepta Therapeutics (US)、PTC Therapeutics (US)、NS Pharma (US)、Santhera Pharmaceuticals (Switzerland)

★調査レポート[世界のデュシェンヌ型筋ジストロフィー治療市場2020:企業別、地域別、種類・用途別] (コード:GIR20MY04869)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のデュシェンヌ型筋ジストロフィー治療市場2020:企業別、地域別、種類・用途別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆